TORgeting oncogene addiction for cancer therapy  by Choo, Andrew Y. & Blenis, John
	 p r e v i e w s
TORgeting oncogene addiction for cancer therapy
The PI3K-Akt-mTOR growth-regulating pathway is conserved from mammals to flies and hyperactivated in many cancers. 
Accordingly, rapamycin analogs, which are inhibitors of mTOR-Raptor signaling, have recently garnered much interest as 
potential therapeutic agents against cancer. However, due to the heterogeneity of tumors, prior knowledge of the genetic and 
biochemical background of cancer cells will be required for effective targeted therapy. Thus, the identification of biological 
markers against activated oncogenic pathways is needed. In the January issue of Nature Medicine, Thomas et al. identify the 
loss of VHL tumor suppressor gene as a potential determining factor in tumor sensitivity to rapamycin.The phosphatidylinositol 3-kinase (PI3K) 
pathway is an evolutionarily conserved 
lipid kinase that initiates a series of growth 
factor-activated signals that provide the 
cell with adequate biosynthesis to meet 
biological demand for basic processes 
such as cellular growth, proliferation, sur-
vival, and bioenergetics. Accordingly, it is 
not surprising that mutations that inappro-
priately activate this pathway are associ-
ated with various malignancies, including 
cancers of the colon, breast, liver, brain, 
stomach, lung, and ovary. PTEN, a nega-
tive regulator of this pathway, is a tumor 
suppressor whose function is lost through 
mutation, inactivation, or silencing in a 
multitude of cancers. For example, PTEN 
mutations have been identified in 45% of 
carcinomas of the endometrium and great-
er than 20% of glioblastomas (extensive 
list reviewed in Ali et al., 1999). Recently, cancer cell February 2006 activating mutations in PI3Kα have also 
been identified in many human malignan-
cies (Bader et al., 2005). Thus, through a 
variety of mechanisms, a high percentage 
of human cancers possess activated PI3K 
signaling. Downstream effectors of the 
PI3K pathway include Akt and the mTOR 
complex 1 (TORC1), which constitutes 
mTOR, Raptor, and mLst8 (GβL). Akt is 
a well-known cell survival kinase (Bader 
et al., 2005) that also phosphorylates and 
antagonizes the tumor suppressor TSC2, 
a GAP that inhibits the G protein Rheb. 
Rheb is a positive regulator of TORC1 
activation that links Akt to cell growth 
control. Thus, Akt integrates PI3K signal-
ing with the TORC1 nutrient and energy-
sensing pathway (Fingar and Blenis, 
2004). It is currently believed that TORC1 
mediates its progrowth effects through 
the activation of S6 kinase 1 (S6K1) and suppression of 4E-BP1, an inhibitor of 
cap-dependent translation (Fingar and 
Blenis, 2004). These observations all 
point to mTOR-Raptor as a critical target 
in cancer therapy, and indeed, rapamycin 
analogs (CCI-779, RAD001, AP23576) 
are currently undergoing clinical trials for 
the treatment of renal cell carcinomas, 
metastatic breast cancers, lymphomas, 
and other malignancies.
Despite the essential role that mTOR 
plays in meeting the biosynthetic demand 
for tumor propagation, early clinical 
results suggest that patient responsive-
ness to mTOR inhibition is variable. For 
instance, a phase II trial against meta-
static melanoma demonstrated that CCI-
779 alone was insufficient to provide 
tumor cytostasis using concentrations 
and a dosing schedule supported by 
phase I and pharmacodynamic studies Figure 1. rapamycin-mediated regulation of 
HIF-1α translation and potential implications 
of long-term rapamycin treatment
aa: mTOr exists in two mutually exclusive 
complexes with raptor or rictor. The rapa-
mycin-insensitive mTOr-rictor complex phos-
phorylates Ser473 on akt, a critical regulatory 
site that is required for activation. Long-term 
rapamycin treatment shifts the equilibrium of 
these two complexes toward mTOr-rictor 
(Sarbassov et al., 2005), leading to increased 
overall akt activity and cellular survival.
ab: rapamycin treatment inhibits a S6K1-
mediated negative feedback loop that 
normally suppresses akt activation. In many 
cancers, the insulin receptor substrate-1 (IrS-
1) is recruited to engaged receptors like the 
IGF-1 receptor and mediates PI3K recruit-
ment to the membrane to generate D-3 
phosphoinositides (PIP3) (yellow phosphates), 
leading to akt activation. S6Ks phosphory-
late IrS-1, promoting its dissociation from the 
receptor, which decreases PIP3 production 
and attenuates akt activation. Thus, in some 
cancers rapamycin can result in increased 
akt activity and tumor cell survival by one or 
both mechanisms.
B: upon growth factor activation, S6K1 is phos-
phorylated by mTOr-raptor at its hydrophobic motif site and released from the eIF3-40S preinitiation complex (PIC). The activated S6K1 then 
phosphorylates eIF4b (Ser/Thr phosphates in pink), which associates with the PIC to function as a cofactor for the rNa helicase eIF4a (see Holz et 
al., 2005). This presumably could augment the translation of the HIF-1α mrNa by alleviating secondary mrNa structural constraints within its 5′uTr 
and hence rendering the process rapamycin sensitive.77
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standing the mechanism for rapamycin 
sensitivity and garnering appropriate 
biological markers for the mTOR path-
way are crucial for predicting possible 
responsiveness to the drug.
In an effort to understand rapamycin 
sensitivity and to identify biomarkers for 
potentially responsive patients, Charles 
Sawyers and colleagues implemented 
the idea of “pathway or oncogene addic-
tion” in tumors and identified the loss of 
the tumor suppressor Von Hippel-Lindau 
(VHL) gene as a determining factor in 
sensitivity to CCI-779 treatment (Thomas 
et al., 2006). The VHL gene encodes an 
E3 ligase that is responsible for ubiqui-
tination and turnover of the α subunit of 
the heterodimeric HIF family of transcrip-
tional factors, which promote expression 
of factors involved in angiogenesis and 
glycolysis (Kaelin, 2005). The authors 
used isogenic pairs of renal cell carci-
nomas differing only in the expression 
of VHL via stable shRNA-mediated 
knockdown. They first showed that cells 
expressing VHL-specific shRNA exhibit-
ed increased HIF-1α/β, GLUT-1, and CA-
IX expression, and cellular proliferation 
presumably through increased HIF-1 sta-
bility and transcription. Surprisingly, cells 
with VHL knockdowns, but not control 
cells, exhibited a profound proliferation 
defect both in culture and in xenograft 
tumor experiments when treated with 
CCI-779. This correlated with a loss of 
HIF-1α expression upon mTOR inhibi-
tion. The effect of CCI-779 on HIF-1α 
was observed in VHL knockdown cells 
under both normoxic and hypoxic con-
ditions, suggesting that mTOR signaling 
is absolutely necessary for expression 
of HIF-1α irrespective of environmental 
conditions.
The authors then provided mecha-
nistic evidence that mTOR regulates 
the translation, but surprisingly not the 
turnover of HIF-1α. More specifically, 
the effect mediated by mTOR required 
the 5′UTR structure of HIF-1α mRNA. 
CCI-779 suppressed translation of the 
wild-type HIF-1α message but not the 
translation of HIF-1/2α ubiquitination 
mutants lacking the 5′UTR region. This 
effect was also observed in xenografts, as 
these tumors were completely recalcitrant 
to CCI-779 treatment when compared to 
the control expressing HIF-1α mRNA 
with a wild-type 5′UTR. The implications 
from these data are that the loss of VHL 
and the subsequent upregulation of HIF-78 1α rendered these tumors “addicted” to 
the proliferative advantage provided by 
the oncogenic activity of this transcrip-
tion factor. Cancer cells lacking VHL are 
then unable to proliferate when suddenly 
deprived of HIF-1α by CCI-779-mediated 
translational repression. Importantly, this 
effect was also observed in other renal 
cell carcinomas with naturally occurring 
VHL mutations.
In an effort to identify a noninva-
sive method for predicting the efficacy 
of CCI-779 treatment, the authors took 
advantage of previous observations 
that prostate cells transformed with Akt 
showed elevated glycolysis likely through 
a HIF-1α- and mTOR-dependent upreg-
ulation of various glycolytic enzymes 
and the glucose transporter GLUT-1 
(Majumder et al., 2004). Accordingly, the 
authors used fluorodeoxyglucose (FDG), 
a glucose analog, as a tracer for positron 
emission tomography (PET) analysis. The 
authors showed that, in xenografts, the 
CCI-779-treated VHL knockdown cells 
exhibited a dramatically decreased abil-
ity to take up FDG. Importantly, this effect 
was not seen when mice bearing the VHL 
shRNA-induced tumors were treated with 
Paclitaxel, suggesting that this effect is 
specific to mTOR inhibition.
The authors hypothesized that the 
mechanism behind the requirement of 
mTOR activation for HIF-1α translation is 
likely through the phosphorylation of the 
40S ribosomal protein S6 by the mTOR 
target S6K1, which has been proposed to 
regulate selective translation of 5′-termi-
nal oligopolypyrimidine (TOP)-containing 
mRNAs, including the HIF-1α message 
(Thomas et al., 2006). However, recent 
evidence suggests that neither S6K1 and 
S6K2 activities nor phosphorylation of S6 
is necessary for translation of 5′ TOP-con-
taining mRNAs (Fingar and Blenis, 2004; 
Ruvinsky et al., 2005). Therefore, it will be 
interesting to determine if in fact S6K1 and 
S6K2 are necessary for the translation of 
HIF-1α. Moreover, mRNAs that possess 
long and structured 5′UTRs are sensi-
tive to mTOR inhibition via the helicase 
activity of the eIF4F complex (Fingar and 
Blenis, 2004), implying that even if S6K1 
and S6K2 are required for translation of 
the HIF-1α mRNA, this effect may not be 
due to the 5′ TOP structure. Accordingly, 
S6K1-mediated phosphorylation of eIF4B, 
an essential cofactor for the eIF4F heli-
case eIF4A, was shown to be required 
for eIF4B recruitment to the 5′ cap com-
plex by interacting with the eIF3:40S preinitiation complex (Holz et al., 2005; 
Figure 1B). Thus, a 5′ TOP-independent 
mechanism remains a possibility, as the 
authors’ 5′UTR constructs were not based 
on mutations but were truncations.
The importance of mTOR in cancer 
cell biology and clinical therapeutics are 
starting to emerge as the implications of 
mTOR in cell growth, proliferation, and 
bioenergetic metabolism are revealed. As 
in all biomedical fields, translating basic 
cancer biology into the clinic is absolutely 
critical, and the work by Thomas et al. 
effectively amalgamates the biochemical 
importance of mTOR into a potential clini-
cal target. However, the focus of this study 
is on HIF-1α-mediated addiction without 
chronic activation of PI3K signaling as is 
observed in many cancers. This leads to 
the question of whether rapamycin will 
be effective in all cancers or if success-
ful treatment will depend on the extent 
of PI3K/mTOR activation. Indeed, recent 
observations are beginning to reveal that 
treatment with rapamycin should be con-
ducted with caution. For instance, a rapa-
mycin-insensitive mTOR complex referred 
to as TORC2 (mTOR-Rictor) exists. 
TORC2 phosphorylates and activates Akt. 
Importantly, long-term rapamycin treat-
ment can dramatically alter the dynamic 
equilibrium between these complexes 
toward TORC2 (Sarbassov et al., 2005). 
In addition, S6K1 provides an inhibitory 
feedback loop that can suppress Akt activ-
ity. Thus, rapamycin treatment may result 
in enhanced Akt activation and enhanced 
tumor growth and survival (Figure 1A). 
Along these lines, RNAi-mediated knock-
down of mTOR, but not rapamycin treat-
ment, can potentiate Taxol-mediated cell 
death in HeLa cells (MacKeigan et al., 
2005 and unpublished data), suggest-
ing that a catalytic inhibitor of mTOR may 
be a more effective antagonist of cancer 
cell proliferation and survival. Rapamycin 
may be more useful in combination with 
other therapies, as reports from several 
groups suggest that rapamycin enhances 
the effects of other anti-cancer agents. For 
instance, rapamycin augments Gleevec-
mediated proliferation inhibition of Bcr-Abl-
expressing cells in vitro and prolongs the 
survival of mice with bone marrow trans-
duced with Bcr-Abl (Kharas and Fruman, 
2005). In some cancer cells, potentiating 
effects on apoptosis have been observed 
when traditional DNA-damaging chemo-
therapeutics were combined with rapa-
mycin (Hennessy et al., 2005). Thus, the 
work by Sawyers and coworkers, and cancer cell February 2006
	 p r e v i e w sstudies combining rapamycin with other 
specific pathway inhibitors and/or tradi-
tional chemotherapeutics, may ultimately 
provide the necessary arsenal to effec-
tively and successfully combat cancer. 
Clearly, the success of this battle will also 
rely heavily on the availability of biomark-
ers that reveal pathway signaling status in 
the malignant cells.
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